Supplementary - Tocilizumab for polyarteritis nodosa
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
Tocilizumab for polyarteritis nodosa. Supplementary data.
应用场景：
创建时间：
2025-01-20
相关数据集
Supplementary Material for: Predictors for 2-Year Functional and Morphological Outcomes of a Treat-and-Extend Regimen with Ranibizumab in Patients with Diabetic Macular Edema
Purpose: The purpose of the study was to investigate longer term functional and morphological outcomes and their predictors in diabetic macular edema (DME) following a treat-and-extend r
DataCite Commons2021-03-19 更新70
Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled” trial (TOCIBRAS)
ABSTRACT Introduction: Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19. Thus, anti-inflammatory therapies are attractive agents for potentially com
NIAID Data Ecosystem50
Unadjusted baseline characteristics of evaluable ICU patients receiving tocilizumab.
Unadjusted baseline characteristics of evaluable ICU patients receiving tocilizumab.
NIAID Data Ecosystem30
Supplementary Material for: Real-world outcomes of ranibizumab treatment in French patients with visual impairment due to Macular Edema secondary to Retinal Vein Occlusion: 24-month results from the BOREAL-RVO study.
Introduction Information about real-world ranibizumab use is needed to optimize treatment of macular edema secondary to retinal vein occlusion (RVO). The BOREAL-RVO study assessed treatment use, effec
DataCite Commons2023-07-22 更新60
Baseline demographics and ocular characteristics for prior ranibizumab-treated patients with nAMD.
Baseline demographics and ocular characteristics for prior ranibizumab-treated patients with nAMD.
Figshare2020-12-30 更新30
